SXTP – 60 degrees pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]
Form 10-Q 60 DEGREES PHARMACEUTICA For: Sep 30
Form SCHEDULE 13G/A 60 DEGREES PHARMACEUTICA Filed by: INTRACOASTAL CAPITAL, LLC
Form SCHEDULE 13G/A 60 DEGREES PHARMACEUTICA Filed by: CVI Investments, Inc.
Form 8-K 60 DEGREES PHARMACEUTICA For: Oct 08
Form 4 60 DEGREES PHARMACEUTICA For: Sep 12 Filed by: DOW GEOFFREY S
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.